Research theme for competitive and other funds (2):
2020 - 2023 非アルコール性脂肪肝炎、新規診断マーカー・治療標的としての糖鎖修飾解析
2015 - 2018 Anti-Adipogenic and Antiviral Effects of L-Carnitine on Hepatitis C Virus Infection
Papers (153):
Hisatoshi Hanamatsu, Goki Suda, Masatsugu Ohara, Koji Ogawa, Nobuharu Tamaki, Hayato Hikita, Hiroaki Haga, Shinya Maekawa, Masaya Sugiyama, Tatsuhiko Kakisaka, et al. Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD. Journal of gastroenterology. 2025. 60. 4. 456-468
Zijian Yang, Goki Suda, Takuya Sho, Osamu Maehara, Masatsugu Ohara, Tomoka Yoda, Qingjie Fu, Takashi Sasaki, Risako Kohya, Sonoe Yoshida, et al. Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
Naohiro Yasuura, Goki Suda, Masatsugu Ohara, Akimitsu Meno, Takuya Sho, Risako Kohya, Takashi Sasaki, Tomoka Yoda, Sonoe Yoshida, Qingjie Fu, et al. Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC. Alimentary pharmacology & therapeutics. 2024
Takuya Sho, Goki Suda, Masatsugu Ohara, Risako Kohya, Takashi Sasaki, Sonoe Yoshida, Shunichi Hosoda, Koji Ogawa, Takashi Kitagataya, Osamu Maehara, et al. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment. Targeted oncology. 2024. 19. 5. 769-778
THE JAPAN SOCIETY OF ULTRASONICS IN MEDICINE
, JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY
, THE JAPAN SOCIETY OF HEPATOLOGY
, JAPANESE SOCIETY OF GASTROENTEROLOGY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE